Drug Trial Radar · NCT03330847
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
273
Actual
Start
Mar 7, 2018
Primary completion
Nov 13, 2020
Study completion Oct 9, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \[AZD6738\]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+ Ceralasertib and olaparib+adavosertib. The study subject population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different schedules of administration of each of the treatment options as well as their different toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1 consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the option of consenting to the main part of the study within the 28-day screening period. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. Patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd). Following the closure of this arm the total number of patients randomised will be lower (approximately 350 patients). Approximately 300 patients will be randomised (using randomisation ratio 1:1) to 2 ongoing treatment arms plus an additional 47 patients to a 3rd arm (olaparib+adavosertib) prior to the arm being discontinued.
Conditions
- Metastatic Triple Negative Breast Cancer
Interventions
Olaparib Continuous (28-Day cycle) 300 mg BD.Drug
Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).Drug
Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).Drug
Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival Per Stratum (BICR)Time frame: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
- Progression-free Survival Per Stratum (Sensitivity Analysis)Time frame: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Locations
141 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Anchorage, Alaska
Research Site
Gilbert, Arizona
Research Site
Aurora, Colorado
Research Site
New Haven, Connecticut
Research Site
Chicago, Illinois
Research Site
Munster, Indiana
Research Site
Hazard, Kentucky
Research Site
Louisville, Kentucky
Research Site
Towson, Maryland
Research Site
Brick, New Jersey
Research Site
East Setauket, New York
Research Site
Lake Success, New York
Research Site
Mineola, New York
Research Site
Mount Kisco, New York
Research Site
Stony Brook, New York
Research Site
Cincinnati, Ohio
Research Site
Knoxville, Tennessee
Research Site
Seattle, Washington
Research Site
Milwaukee, Wisconsin
Research Site
Brasschaat, Belgium
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Namur, Belgium
Research Site
Ottignies, Belgium
Research Site
Wilrijk, Belgium
Research Site
Calgary, Alberta, Canada
Research Site
Kelowna, British Columbia, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Brno, Czechia
Research Site
Olomouc, Czechia
Research Site
Prague, Czechia
Research Site
Angers, France
Research Site
Besançon, France
Research Site
Bordeaux, France
Research Site
Caen, France
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.